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Abstract
Background: The activity of one of the major catechins in Green Tea, the polyphenol (−)-epigallocatechin-3-gallate
(EGCG), has been shown to have a variety of health benefits. Recent studies suggest that EGCG can modulate
both the innate and adaptive arms of the immune system. The goal of the current studies was to examine
the immunomodulatory effects and mechanisms of action of EGCG on experimental arthritis in mice.
Methods: EGCG (10 mg/kg) was administered by oral gavage after CIA induction, while control mice were administered
phosphate buffered saline (PBS). Disease mechanisms were studied in both groups of mice. Phenotypes were examined
using repeated measure analysis of variance (ANOVA) and data from in vitro and ex vivo experiments were analyzed for
significance using the Mann-Whitney U test.
Results: EGCG treatment ameliorated clinical symptoms and reduced histological scores in arthritic mice. Serum type-II
collagen-specific immunoglobulin (Ig) IgG2a antibodies were significantly lower in EGCG-fed mice compared to PBS-
treated mice. EGCG significantly suppressed T cell proliferation and relative frequencies of CD4 T cells, CD8 T cells and B
cell subsets including marginal zone B cells, T1 and T2 transitional B cells, while increasing the frequency of CD4+ Foxp3+
regulatory T cells (Tregs) and indoleamine‐2,3‐dioxygenase (IDO) expression by CD11b+ dendritic cells (DC). Splenic
CD11b+ DC from EGCG fed mice induced an increased frequency of Tregs via an IDO-dependent mechanism in in vitro
cultures. Importantly, joint homogenates from EGCG-fed mice exhibited significantly increased levels of Nuclear Factor,
Erythroid 2-Like 2 (Nrf-2) and Heme oxygenase-1 (HO-1) compared with PBS-fed mice.
Conclusions: This is the first report of upregulation of the Nrf-2 antioxidant pathway in EGCG-mediated
immunoregulation. EGCG ameliorated experimental arthritis in mice by eliciting IDO-producing DCs, increasing frequencies
of T regs and inducing the activation of the Nrf-2 antioxidant pathway. It remains to be established whether EGCG is useful
for the prevention and treatment of rheumatoid arthritis and other inflammatory disorders.
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Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune dis-
ease characterized by leukocyte infiltration and inflamma-
tion in the synovial membranes of joints. Inflammation
contributes to pannus formation and ultimately destruc-
tion of articular bone and cartilage [1–3]. The features of
disease can be severely debilitating with pulmonary, renal
and cardiovascular involvement in addition to joint de-
struction leading to significant functional disability and in-
creased morbidity [2].
Conventional therapies such as non-steroidal anti-in-
flammatory drugs (NSAIDs) and disease modifying anti-
rheumatic drugs (DMARDs) along with biologics and other
experimental treatments have been used to slow the clinical
progression of RA [4–7]. Unfortunately, these agents have
limited efficacy and serious side effects [8–11]. Thus, an
important goal of RA therapy is to move toward therapies
that have the potential to induce remission of disease activ-
ity and thereby control the accumulation of irreversible
joint damage with fewer side effects [12, 13]. Over the last
decade, the use of biologics including IL-1, IL-6 and
TNF-α blockers have shown efficacy for the treatment
of disease in some patients; however, their effectiveness
is incomplete and there is a sizeable population of non-
responders [12, 13]. Due to the limitations of conven-
tional drugs and newer biologics, there is a growing
interest in the use of herbal products with complemen-
tary activities to halt the progression of arthritis and in-
flammatory autoimmune diseases.
Green tea, which is a rich source of the immunomodula-
tory polyphenol (−)-Epigallocatechin-3-gallate (EGCG), is
one of the most commonly consumed beverages in the
world. EGCG has been shown to have antioxidant and
anti-inflammatory effects in various animal models of auto-
immune diseases [14–19]. In the past decade, the cartilage-
preserving and chondroprotective action of EGCG has
been verified in several studies [15, 16]. Moreover, EGCG
pretreatment in an experimental immune-mediated glom-
erulonephritis model reduced oxidative stress and normal-
ized levels of glutathione peroxidase and peroxisome
proliferator-activated receptor-γ [17]. EGCG inhibited Th1
and Th17 cells and increased T regulatory cell (Treg) de-
velopment in experimental autoimmune encephalomyelitis
(EAE) models [18]. The disease-modifying effects of green
tea extract on arthritis in a collagen-induced arthritis (CIA)
murine model was associated with reduced inflammatory
mediators including COX-2, IFN-γ and TNF-α in arthritic
joints [15, 20]. Kim and colleagues have reported that
Lewis rats fed with green tea extract in drinking water ex-
hibited significantly reduced severity of adjuvant-induced
arthritis (AA) and decreased serum levels of antibodies
[19]. Using in vitro cultured primary human osteo-
blasts and an in vivo rat CIA model, another study
demonstrated that EGCG was able to ameliorate
arthritis in rats, associated with reduced MCP-1/CCL2
and GRO/CXCL1 synthesized by osteoblasts [21]. Al-
though EGCG suppresses arthritis in animal models,
the underlying mechanisms regulating immune cell ac-
tivity have yet to be delineated. In this study, we exam-
ine the effects of EGCG on clinical arthritis, as well as




Approximately 8-week-old male DBA/1 J mice (The
Jackson Laboratory, Maine, USA) were maintained in
groups of two to four animals in polycarbonate cages
in a specific pathogen-free environment and were fed
standard chow (Ralston Purina, St Louis, MO, USA) and
water ad libitum. All experimental procedures were exam-
ined and approved by the Institutional Care and Use Com-
mittee at the University of Texas Southwestern Medical
Center at Dallas.
Oral feeding of EGCG in DBA/1 mice
DBA/1 mice were orally fed with either phosphate buff-
ered saline (PBS) control or EGCG (10 mg/kg, Sigma, in
PBS) using an oral gavage Zonde needle (Thermo Fisher
Scientific, Vantaa, Finland), nine times over three weeks,
beginning a week after booster immunization.
Induction and evaluation of arthritis
Bovine type II collagen (CII) was dissolved in 0.05 N acetic
acid and was emulsified (1:1 ratio) with an equal volume of
complete Freund's adjuvant (CFA); both CII and CFA from
Chondrex, Redmond, WA [22, 23]. Mice were immunized
by tail base injection on day 0 with an emulsion of CII
(100 μg) and CFA (1 mg/ml), followed by a booster in-
jection at a separate site at the base of the tail with an
emulsion of CII (100 μg) in incomplete freund's adjuvant
(1:1) on day 14 [23]. Starting 18 days after the primary
immunization, three independent observers examined the
severity of arthritis three times a week for up to 6 weeks.
The severity of arthritis was recorded as the mean arthritic
index on a 0 to 4 scale according to the following criteria:
0 = no edema or swelling; 1 = slight edema and erythema
limited to the foot or ankle; 2 = slight edema and erythema
from the ankle to the tarsal bone; 3 =moderate edema and
erythema from the ankle to the tarsal bone; and 4 = edema
and erythema from the ankle to the entire leg [22]. The
final score was an average value of three independent joint
evaluations.
Measurement of autoantibodies
Blood was collected from the orbital sinus of EGCG-
treated and control mice at the peak of clinical disease.
Serum specimens were stored at −20 °C until use, and anti-
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CII IgG1 and anti-CII IgG2a Ab levels were measured by
an enzyme-linked immunosorbent assay (ELISA). Mi-
croplates were coated with 4 μg/ml of CII overnight
and blocked with 1 % bovine serum albumin (BSA)
from Sigma-Aldrich, St. Louis, MO and then incubated
with sera at a dilution of 1:16,000. Bound total or CII-
specific IgG1 or IgG2a were detected by incubation
with horseradish peroxidase (HRP)-conjugated goat anti-
mouse IgG1 or IgG2a-specific antibodies (cat # A90-205P
and A90-207P from Bethyl Laboratories, Inc., Montgomery,
TX) for 1 h. Then the plates were washed with phosphate-
buffered saline with Tween 20 buffer (PBST) and developed
with 3,3',5,5'-tetramethylbenzidine (TMB) substrate accord-
ing to the manufacturer’s instructions (Sigma-Aldrich). The
reaction was terminated with 4.5 N sulfuric acid (H2SO4).
The optical density (OD) values were measured at 450 nm
using an Automatic Microplate Reader (BLx808, BIO-TEK,
Winooski, Vermont).
Flow cytometry and antibodies
Red blood cells were depleted from splenocytes and lymph
node cells using lysis buffer which contained 10 mM po-
tassium bicarbonate (KHCO3), 0.15 M ammonium chlor-
ide (NH4Cl) and 0.1 M ethylenediaminetetraacetic acid
(EDTA), pH 7.2, and single cell suspensions were prepared
and flow cytometric analysis was performed using a
FACSCalibur (BD Biosciences, San Jose, CA) with BD Cell-
Quest Pro Software (BD Biosciences) and the data was ana-
lyzed using FloJo Software (FlowJo, LLC, Ashland, OR).
For analysis of lymphocytes the following rat anti-mouse
antibodies were used: CD4-PerCP-Cy5.5 (clone RM4-5),
CD8-PE (clone 53–6.7), CD21/35-FITC (clone 7G6) and
CD23-Biotin (clone B3B4) with Streptavidin- allophycocya-
nin (APC); all antibodies and second step reagents from
BD Biosciences. Tregs were identified using anti-mouse
FoxP3-FITC (clone FJK-16a; eBioscience) and CD25-
APC (clone 3C7; Biolegend). CD11b+ cells were identi-
fied using rat anti-mouse CD11b-PerCP (clone M1/70;
BD Biosciences) and indoleamine‐2,3‐dioxygenase (IDO)-
positive cells were detected with rat anti-mouse IDO
(clone mIDO-48; Biolegend) followed by FITC goat anti-
Rat Ig secondary antibody (cat# 554016, BD Biosciences).
Intracellular Staining for IFN-γ and TNF-α
Single cell suspensions isolated from draining lymph
nodes were stimulated with 25 ng/ml PMA (Sigma) and
250 ng/mL ionomycin (Sigma). GolgiStop (BD Biosciences)
was added and the cells were harvested after 5 h of cul-
ture. Cells were first stained extracellularly with anti-
CD4 PerCP-Cy5.5-conjugated (clone RM4-5) antibody,
then fixed and permeabilized with Perm/Fix solution,
and finally stained intracellularly with anti- IFN-γ FITC-
conjugated (clone XMG1.2), and anti- TNF-α PE-
conjugated (clone MP6-XT22) antibodies. Directly
conjugated isotype-matched rat anti-mouse antibodies were
used as controls for nonspecific staining. All reagents
for fixation and staining were from BD Biosciences and
the protocol was carried out following the manufac-
turer’s instructions.
3H-thymidine incorporation in mouse spleen and draining
lymph nodes cells
Draining inguinal lymph nodes (dLNs) were aseptically ex-
cised, minced and single cell suspensions were cultured in
triplicate in RPMI 1640 containing fetal calf serum
(10 % vol/vol), 2-mercaptoethanol (20 μM), L-glutamine
(1 % wt/vol), penicillin (100 U/mL), and streptomycin
(100 μg/mL) in the presence or absence of CII (Chondrex)
or rat anti-mouse CD3 antibody (clone 17A2; BD Biosci-
ences). During the last 16–18 h of the three-day assay, cells
were pulsed with 1 uCi of [3H]-thymidine (Perkin Elmer,
Waltham, MA) per well. The incorporation of [3H]-thymi-
dine was determined using a Betaplate scintillation counter
(Perkin-Elmer, Waltham, MA).
Preparation of tissue homogenates and western blotting
Hind paws and knees were removed from the sacrificed
mice, frozen in liquid nitrogen and lysed using a buffer
containing 20 mM Tris–HCl (pH 7.5), 150 mM NaCl,
1 mM Na2EDTA, 1 % Triton X-100, protease inhibitor
cocktail (Complete Mini, Roche, Indianapolis, IN) and
phosphatase inhibitor cocktail (PhosSTOP, Roche, In-
dianapolis, IN). The crude extract was then sonicated
for 30 s. The homogenate was centrifuged at 20,000 X g
for 15 min, and the resulting supernatant was collected.
The total protein content of samples was quantified using
the Bradford assay (Sigma). 10 μg of each sample was re-
solved by sodium dodecyl sulfate polyacrylamide gel elec-
trophoresis (SDS-PAGE) using a 4–15 % Mini-PROTEAN
TGX Precast Gel (Biorad, Hercules, CA), transferred to a
polyvinylidene difluoride (PVDF) membrane (Biorad,
Hercules, CA), and probed with primary antibodies in-
cluding rabbit antibody to Nuclear Factor, Erythroid 2-
Like 2 (anti-Nrf2; catalog no. ab31163), rabbit antibody to
phosphorylated Nrf-2, anti-p-Nrf2 (ab76026) and a
mouse IgG1 monoclonal antibody that recognizes
mouse heme oxygenase-1, anti-HO-1 (ab13248, clone
HO-1-1); all from Abcam and all have been previously
shown to react with murine proteins. The loading con-
trol was an anti-GAPDH (clone 6C5; Advanced Immu-
noChemical) which reacts to mouse and other species.
Appropriate HRP-conjugated secondary antibodies which in-
cluded goat anti-rabbit or goat anti-mouse (Jackson Immu-
noResearch) were used at 1:5000 and detected with the
SuperSignalWest Femto Chemiluminescent Substrate
Kit (Thermo Scientific). Protein expression levels were
visualized and quantitated using the gel documentation
system, G:BOX (Syngene, Frederick, MD).
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Measurement of IDO Enzymatic Activity
The indoleamine‐2,3‐dioxygenase (IDO) enzyme activity
assay was performed as previously reported [24] with
some modifications. In brief, freshly isolated DCs were
washed, resuspended in sterile Hank’s Balanced Salt Solu-
tion (HBSS; Sigma-Aldrich) containing 500 uM trypto-
phan (Sigma-Aldrich), and incubated for 4 h. The
supernatants were then harvested and assayed for kynure-
nine. For the assay, 30 ul of 30 % trichloroacetic acid was
added to 60 ul of culture supernatant and the mixture was
vortexed and centrifuged at 10,000 X g (12,000 rpm) for
5 min. Then, 40 ul of supernatant was added to an equal
volume of Ehrlich reagent (5 ml of glacial acetic acid with
100 mg P-dimethylamino-benzaldehyde). The OD was
measured at 492 nm using a NanoDrop (LMS). Purified L-
kynurenine (0–500 uM; Sigma-Aldrich) was used as the
standard.
Fluorescence microscopy
Spleens from mice were collected, embedded in Tissue-Tek
Optimal Cutting Temperature (O.C.T.) compound and
snap-frozen in liquid nitrogen. Cryosections (6 μm thick)
were fixed with 4 % paraformaldehyde, blocked with 10 %
horse serum for 30 min and stained with various antibodies.
Anti-Foxp3-FITC (clone FJK-16a; e-Bioscience) and anti-
IDO (clone mIDO-48; Biolegend) or Rat IgG2b isotype
control (Biolegend) were detected with goat anti-rat
Alexa-555 secondary (catalog # A-21434; Invitrogen)
and anti-APC-CD11b (clone M1/70; BD Bioscience).
Fluorescence images were acquired using an LSN510
confocal microscope (Carl Zeiss, Oberkochen, Germany).
For quantification of immunofluorescence (IF) 10 repre-
sentative high-powered fields per slide were assessed
from at least 4 to 5 samples/group.
Detection of Cytokine Production by Enzyme-Linked
Immunosorbent Assay (ELISA)
Serum specimens were assayed for IL-1β, IL-6, IFN-γ,
TNF-α and IL-10 by ELISA using Duoset assay kits from
R&D Systems and following the manufacturer’s instructions.
Co-culture of DC with T cells
Mice were sacrificed seven weeks after immunization. The
spleens obtained from the mice were treated with RPMI
1640 (Invitrogen) containing dithiothreitol (DTT) and
EDTA for 90 min at 37 °C to remove the epithelial
cells and then washed with HBSS and digested with
DNase. CD11b+ DCs cells were separated from spleno-
cyte suspensions from EGCG-fed or PBS-fed mice using a
mouse CD11b positive selection kit (catalog # 18770; Stem
Cell, Canada) and were co-cultured with CD4+CD25− T
cells isolated from EGCG-fed mice for 3 days in the pres-
ence or absence of CII (10 μg/ml, Chondrex Inc, USA).
Before the stimulation with CII, the cells were pretreated
with the IDO-specific inhibitor 1-methyl dL tryptophan (1-
MT), obtained from Sigma-Aldrich, for two hours. To
measure the amount of intracellular Foxp3 in CD4+CD25+
Tcells, cells were stained using a Regulatory T Cell Staining
Kit (eBioscience, San Diego, CA, USA) as described in flow
cytometry above.
Histology of joint tissues
Hind paws and knees were obtained from each mouse,
the skin was trimmed, and the joints were fixed in 10 %
phosphate-buffered formalin for 1 day, decalcified in 15 %
EDTA for 3 weeks and embedded in paraffin. Tissue sec-
tions (6 μm) were prepared and stained with hematoxylin,
eosin and safranin O. Inflammation and joint damage were
assessed by scoring five parameters. Disease was scored on
a scale of 0 to 3 for inflammation ranging from no inflam-
mation to severe inflammation, loss of proteoglycans
ranging from fully stained to destained cartilage, cartil-
age destruction ranging from appearance of dead chon-
drocytes to complete loss of the articular cartilage, and
was scored on a 0 to 5 scale for loss of bone ranging from
no damage to complete loss of bone structure. For hist-
ology of both knee and paw, a composite score was calcu-
lated by summing the individual parameters.
Inhibition of IDO with 1-Methyl-dL-Tryptophan
1-MT was obtained from Sigma-Aldrich and was prepared
as a 20-mmol/l stock in 0.1 N NaOH (pH 7.4) and stored
at −20 °C in the dark. EGCG fed mice were given 2 mg/ml
1-MT solution, supplemented with aspartame using foil-
wrapped, standard autoclaved drinking bottles. Mice drank
an average of 5 ml/d, and water was replaced as needed
for 3 weeks.
Statistical analysis
Phenotypes were examined using repeated measures one-way
analysis of variance (ANOVA), with treatment and time as
fixed factors and mouse number as the random factor. Data
from in vitro and ex vivo experiments were analyzed for stat-
istical significance using the Mann-WhitneyU test (GraphPad
Prism 6, GraphPad Software, Inc., San Diego, CA, USA).
A p value < 0.05 was taken as the level of significance. In all
experiments, * indicates P< 0.05, ** P< 0.01, and *** P< 0.001.
Results
EGCG treatment reduces disease activity in collagen-
induced arthritis
We determined whether EGCG modulated disease activity
in a murine collagen-induced arthritis (CIA) model. DBA/1
mice were immunized on days 0 and 14 with bovine type II
collagen (CII), as detailed in the methods. Mice were fed
with EGCG nine times over three weeks with 10 mg/kg,
starting on day 21 after induction of arthritis throughout
the disease course and vehicle-fed or EGCG-fed mice were
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observed for 49 days for the development of clinical
arthritis (Fig. 1). Mice treated with PBS (vehicle control)
developed the typical signs of CIA both in terms of
clinical score and paw swelling seven weeks after the
initial immunization (Fig. 1a, b). In contrast, EGCG-
treated mice displayed a significant decrease in severity of
arthritis and paw thickness compared to animals treated
with vehicle alone (Fig. 1a, b). As expected, vehicle-fed
CIA mice developed severe symptoms of arthritis includ-
ing marked swelling, redness, and erythema of the hind
paws and the forepaws. In contrast, EGCG-fed mice
exhibited markedly reduced clinical manifestations of fully
developed CIA (Fig. 1c).
The observed clinical paw inflammation was also con-
firmed by assessment of H&E stained histological sections
of mouse hind paws. The histological images of the paws
shown in Fig. 1d are representative of mice in each group
at day 49 when disease was found to be at its maximum.
Joint tissue samples from arthritic vehicle-fed mice revealed
the expected histopathological changes, including marked
synovial hyperplasia, erosion, and loss of articular cartilage
and bone. In this group, there was extensive cartilage and
bone erosions with massive infiltration of polymorpho-
nuclear and mononuclear leukocytes as indicated by the
elevated histopathological score (Fig. 1e). The joint swell-
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Fig. 1 CIA induction and EGCG administration in CII-immunized DBA/1 J mice. a Effects of EGCG on arthritis score of CIA mice. DBA1/J mice (DBA-1)
were untreated or immunized with 100ug CII in complete CFA. A booster injection of 100 ug of CII was given on day 14 to induce CIA
in mice. Beginning on day 21 post CII immunization, 10 mg/kg EGCG was administered orally using oral gavage for nine successive times
every two days over the course of three weeks. PBS was given to the CIA control group over the same time period. Mice were sacrificed
on day 49 for immunophenotypic analysis and histopathological examination, *P< 0.05, **P< 0.01. N= 4 to 5 mice per group for each experiment, with a
total of 14 mice per group; *P< 0.05; **P< 0.01. N= 14 mice for each group. Data shown is representative of three independent experiments. b Effects of
EGCG on paw swelling of CIA mice. Mice were untreated DBA-1 or immunized with CII as described above and treated with PBS (vehicle) or EGCG. All
data are shown as mean ± SEM of three independent experiments. N= 4 to 5 mice per group for each experiment, with a total of 14 mice per
group. c Representative photographs depicting vehicle-fed (upper) and EGCG-fed CIA mice (lower) on day 49 after 1st immunization. d Histopathology
of paw and knee joints from representative CIA mice treated with vehicle (left) or EGCG (right). Joints were harvested on day 49 and
joints were decalcified and stained with H&E (original magnification × 40). Five mice were examined per group. e Values of histological
scores are shown as mean ± SEM derived from five mice per group for synovial inflammatory infiltrate, cartilage degradation and bone
erosion. f Serum titers of CII-specific IgG2a were detected by ELISA in the individual EGCG (n = 14) or vehicle-fed mice (n = 14). Serum
samples were obtained on day 49 post first CII immunization. The results were calculated in arbitrary units and are expressed as mean ± SD
of three independent experiments, ∗∗P < 0.01
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disease severity. A similar analysis of arthritic joints from
the EGCG-fed group showed a marked reduction in the
number of infiltrating leukocytes, with less visible cartil-
age or bone erosion when compared with the vehicle-fed
CIA mice (Fig. 1d, e). Thus, these results indicate that
EGCG reduced infiltration of inflammatory cells and
diminished the severity of arthritis as assessed by clinical
and histological scores. Consistent with previous reports,
our results demonstrate that the oral administration of
EGCG successfully ameliorates disease activity in an in-
flammatory arthritis model.
EGCG reduces serum levels of type II-collagen-specific
IgG2a antibodies
Previous studies have shown that humoral immunity plays
an essential role in the pathogenesis of CIA [25, 26]. Our
results indicate that, in EGCG-treated mice CII-specific
IgG2a antibodies were dramatically reduced (P < 0.01) when
compared to vehicle-fed CIA mice (Fig. 1f). In contrast, the
titers of anti-CII specific IgG1 antibodies were increased in
EGCG-treated mice compared with vehicle-treated mice
(P < 0.5; data not shown). These results suggest an import-
ant role for EGCG in modulating B cell responses, as well
as Th1/Th2 balance in the ongoing immune response.
EGCG treatment reduces serum and joint inflammatory
cytokine production
Previous reports have shown that arthritis is associated with
the presence of Th1 CD4+ T effector cells secreting high
levels of IFN-γ while there is an absence of Th2 effectors in
the arthritic synovium in murine CIA models and RA
[20, 25, 27]. IFN-γ induces activation of macrophages
that produce proinflammatory cytokines, such as TNF-
α and IL-1β which are abundant in arthritic joints in
animal models and RA [25, 28, 29]. We therefore mea-
sured pro-inflammatory cytokines in the serum and
knee homogenates of the experimental mice (Fig. 2). At
day 49 after induction of CIA, EGCG significantly re-
duced serum levels of IL-6, TNF-α, and IFN-γ com-
pared to vehicle-fed control CIA mice. However, there
was no statistical difference in the production of IL-1β
while IL-10 levels were elevated in the serum of EGCG-
fed mice (Fig. 2a). Similar results were obtained when
pro-inflammatory cytokines were measured in knee
homogenates (Fig. 2b). The levels of IL-1β, IL-6, TNF-α
and IFN-γ were significantly lower and IL-10 was
higher in EGCG-fed mice when compared with vehicle-
fed CIA mice. We also quantitated the frequency of
cells producing Th1 cytokines including IFN-γ and
TNF-α in the draining lymph nodes of EGCG-fed mice
and vehicle-fed control mice (Fig. 2c, d). In concord-
ance with the results for the serum and joint cytokine
profiles, Th1 cell frequencies were significantly reduced
in the EGCG-fed mice as compared to the controls.
Our results suggest that consumption of EGCG limited
inflammatory Th1 cell numbers and cytokines, which
may have contributed to the altered anti-CII antibody
isotype profiles and reduced disease severity.
Alteration of CIA-induced immune cell populations by
dietary EGCG
RA is characterized by chronic inflammation of the syno-
vium which could result in part from the infiltration of ac-
tivated immune cells including CD4+ T cells, B cells, and
antigen presenting cells including DC and macrophages
[2, 20, 27, 29]. To identify the changes in immune cell
populations after EGCG supplementation, we conducted
flow cytometric analysis (Fig. 3). EGCG reduced the
frequencies of B cells (CD5−B220+) and the major T-cell
subsets (CD4+CD8− and CD4−CD8+) in the dLNs on day
49 in CIA (Fig. 3a, b, d). We next examined the frequen-
cies of different splenic B cell subsets including the
follicular (Fo, CD21intCD23hi) and marginal zone (MZ,
CD21hiCD23lo) B cells [30]. EGCG treatment significantly
reduced the frequencies of Fo and MZ B cells in the
spleen (Fig. 3c, d). Finally, mice treated with EGCG had
significantly increased frequencies of CD4+CD25+Foxp3+
T-regulatory (Treg) cells in the dLNs (Fig. 3e, f ). There
was an average 2-fold increase in Treg frequencies in
EGCG-treated mice compared to the vehicle-fed CIA mice.
EGCG treatment attenuates T cell proliferation in CIA
Activation and cytokine production by CD4+ T cells play
an important role in the pathogenesis of inflammatory
arthritis. Upon antigen encounter, clonal expansion of
Ag-specific T cells is a prerequisite for the initiation and
development of the T-cell mediated immunopathological
features [20, 22, 23]. We next determined whether
the EGCG-induced reduction in severity of murine CIA
might be mediated by its impact on Ag-specific T-cell re-
sponses. Draining lymph nodes (dLN) were collected from
collagen-immunized/boosted DBA/1 mice after 49 days
following vehicle or EGCG treatment. Cells cultured in
the absence of CII, exhibited basal levels of DNA synthe-
sis, as measured by incorporation of [3H]-thymidine, that
did not differ between the vehicle-fed and EGCG-fed
groups (Fig. 4a, b). In contrast, cells from vehicle-fed mice
cultured in the presence of CII exhibited a robust antigen
recall response, which was significantly reduced in cells
derived from EGCG-fed mice (Fig. 4a). Mice treated
with EGCG also demonstrated significantly reduced T
cell DNA synthesis when stimulated with anti-CD3 (Fig. 4b).
Consistent with the above results, CFSE assays demon-
strated that EGCG reduced CD4+ T cell proliferation
(Fig. 4c, d). These results indicate that administration
of EGCG attenuates antigen-induced T cell prolifera-
tion in murine CIA.
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EGCG induction of IDO expression by CD11b+ dendritic
cells in CIA
IDO is an intracellular enzyme that catabolizes the essential
amino acid tryptophan, expressed in monocytes, dendritic
cells (DC) and macrophages. IDO has been shown to
suppress T cell proliferation by mechanisms that remain to
be elucidated [31]. Active IDO can be induced by IFN-γ,
endotoxin, a CTLA-4 fusion protein via CD80/CD86
ligation and the combination of PGE2 and TNF-α [24, 32].
A previous study demonstrated that IDO expressing DC in
Peyer’s patches play an essential role in the induction of oral
tolerance in CIA [31]. To examine whether DC in EGCG-
fed mice express IDO as one mechanism for subduing CIA,
we performed immunofluorescence staining for IDO and
CD11b on tissue sections of dLN obtained on day 49 after
disease induction. As shown in Fig. 5a, b, IDO staining (red)
was clearly increased in a substantial proportion of the
CD11b+ DC (blue) from the dLN of EGCG-fed mice as
compared to the vehicle controls. Consistent with the above
results, flow cytometric analysis of the dLN and spleens
revealed that the CD11b+IDO+ DC were significantly in-
creased after EGCG treatment (Fig. 5c, d). We next exam-
ined whether the DC-expressed IDO was enzymatically
active. As shown in Fig. 5e, the culture supernatants of
CD11b+ DC isolated from EGCG-fed mice contained
high levels of kynurenine, the first catabolite in the tryp-
tophan metabolic pathway, compared to the controls.
These studies demonstrate that the EGCG-induced IDO
expressed by CD11b+ DCs was functionally active.
IDO-expressing CD11b+ DC are required for CD4+CD25+
Treg generation in vitro
We next investigated whether the CD11b+ DC induced by




Fig. 2 Proinflammatory cytokine expression in EGCG-fed CIA mice. Changes in the levels of IL-1β, IL-6, TNF-α, IFN-γ and IL-10 were measured in
a sera and b joint homogenates using ELISA assays and joint samples were normalized by protein concentration. All data are shown as mean ±
SEM from three independent experiments involving 4 to 5 mice per group (*P < 0.05; **P < 0.01; ***P < 0.001). c,d The draining lymph node cells
from CIA mice treated with EGCG or vehicle were cultured with PMA (25 ng/ml) and ionomycin (250 ng/ml) in the presence of a protein export in-
hibitor for 5 h. Frequencies of TNF-α and IFN-γ expressing CD4+ T cells were assessed by intracellular staining and flow cytometric analysis. Frequencies
of TNF-α and IFN-γ were significantly reduced in the EGCG-fed mice as compared to controls whereas frequencies of TNF-α+ IFN-γ+ cells were
similar between the two groups. The results shown were from one representative experiment of three independent experiments
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(Treg). Highly purified CD4+CD25− T cells isolated from
the spleen of EGCG-fed mice (purity > 97 %) were cocul-
tured with CD11b+ DC from EGCG or vehicle-fed control
CIA mice for 3 days in the presence or absence of CII.
Figure 6a,b shows that the frequency of CD4+CD25
+Foxp3bright T cells was increased when CD4+CD25− T
cells were co-cultured with CD11b+ DC from EGCG-
fed CIA mice in the presence of CII antigen than when
CD4+CD25− T cells were co-cultured with CD11b+ DC
from vehicle-fed CIA mice. To determine whether IDO
was mechanistically involved in DC-mediated antigen-
specific Treg generation after EGCG treatment, 1-MT,
an IDO inhibitor, was added to the CII antigen-stimulated
cultures. Indeed, 1-MT abrogated the increase in the pro-
portion of CD4+CD25+ Foxp3+ T cells induced by CD11b+
DC from EGCG-fed CIA mice (Fig. 6a, b) which correlated
with arthritis scores (Fig. 6d). Thus, our findings dem-
onstrate that highly purified CD4+CD25− T cells can
be converted into T regulatory cells (Tregs) by splenic
DC obtained from EGCG-fed mice by antigen-specific
stimulation with CII through an IDO-dependent mechan-
ism. Previous studies have demonstrated the presence of
IDO expressing cells frequently juxtaposed to Tregs in
other disease models. For example, IDO expressing mye-
loid DC and macrophages in cutaneous granulomas were
adjacent to Foxp3+ cells [33]. We next investigated whether
EGCG treatment promoted a physical association between
IDO expressing CD11b+ DC and Tregs in the spleen. Im-
munofluorescence analysis of EGCG-treated mice revealed
that Foxp3 and IDO expressing CD11b+ cells were present
and adjacent to each other in spleens to a greater extent
than in control vehicle-treated mice (Fig. 6c). Thus, these
studies correlate with the in vitro observation that IDO
expressing CD11b+ DC can augment Treg numbers.
EGCG treatment suppresses arthritis by enhancing Nrf2
activity through an IDO-dependent mechanism in vivo
Nuclear factor, erythroid 2-like 2 (Nrf-2) is a transcription
factor that plays a major role in cellular defense against







Fig. 3 EGCG suppresses lymphocyte responses to antigen stimulation in CIA. Subsets of T cells from draining lymph nodes (dLN) and B cells from
spleen in vehicle-fed or EGCG-fed CIA mice were examined for frequencies by flow cytometry in three independent experiments with 4 to 5 mice
per group. a,b Representative data for major T lymphocyte subsets of CD4+ (CD4 + CD8 -) and CD8+ (CD4− CD8 +) T cells from the dLN
are shown. c,d dLN B cells (CD5−B220 +) and splenic B cell subsets were assessed including splenic marginal zone B cells (B220 + CD23−CD21 +) and
splenic follicular B cells (B220 + CD23 + CD21−). The absolute number of marginal zone B cells (5.0 × 107 cells ± 0.8 vehicle-fed vs 1.5 × 107
cells ± 0.1 EGCG-fed, P < 0.01) and follicular B cells (1.9 × 107 cells ± 0.2 vehicle-fed vs 0.3 × 107 cells ± 0.04 EGCG-fed, P < 0.01) in CIA mice
were significantly reduced in numbers following EGCG treatment. e,f Representative data shows EGCG treatment increased the number of
CD4+Foxp3+ T cells recovered from the dLN as compared to vehicle-fed CIA mice
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oxygenase-1 (HO-1), that inactivate reactive oxygen
species. Increased levels of Nrf-2 result in enhanced
antioxidant activity, which then suppresses inflamma-
tion in several animal models [34–36]. Although in-
creases in total Nrf2 expression was variable in joint
homogenates, there was a consistently dramatic enhance-
ment of phosphorylation of Nrf2 (p-Nrf2), indicating pNrf2
activation, observed in arthritic joint homogenates of
EGCG-fed compared with vehicle-fed CIA mice (Fig. 7a).
The level of p-Nrf2 was significantly elevated in EGCG-
fed CIA mice compared with control vehicle-fed mice as
determined by densitometry Fig. 7b. We also examined
the expression of HO-1, a downstream target of Nrf2.
In EGCG-fed animals, HO-1 protein was significantly
increased compared with vehicle-fed CIA mice and by
densitometry EGCG treatment increased total HO-1/GAPDH
ratios relative to control vehicle-fed mice (Fig. 7a, b).
IDO plays a pivotal role in the inflammatory pathology
associated with systemic autoimmunity and disease pro-
gression [32]. We next examined whether the function
of IDO was in part related to the activation of Nrf2
observed in these mice. Thus, EGCG-fed CIA mice were
treated with the IDO inhibitor 1-MT for three weeks and
monitored for the development and severity of arthritis.
1-MT treated EGCG-fed mice displayed arthritis that was
similar to the vehicle-fed control CIA mice. Immuno-
histochemical analysis of knee joints demonstrated that
p-Nrf2 expression was enhanced in EGCG-fed CIA mice
and that this increased expression was blocked by 1-MT
(Fig. 7e). Examination of Safranin-O stained paws from
CIA mice demonstrated that EGCG-fed mice were pro-
tected from cartilage degradation in contrast to vehicle-fed
and EGCG-fed mice treated with 1-MT (Fig. 7e). In further
support of these results, p-Nrf2, Nrf2 and HO-1 from joint
homogenates were examined by western blot (Fig. 7c, d).
1-MT-treated EGCG-fed CIA mice had similar levels of all
three molecules as compared to vehicle-fed control CIA
mice. EGCG-fed mice expressed increased levels of p-Nrf2
as well as total Nrf2 and HO-1. These results are consist-
ent with an IDO-dependent mechanism of enhanced Nrf2
expression in the inflamed joints of CIA mice.
Discussion
Rheumatoid arthritis (RA) is a chronic inflammatory dis-
ease characterized by T-cell mediated inflammation which
contributes to the destruction of cartilage and bone in the
joints [14–16, 25]. In animal models, CIA induced by in-











































Fig. 4 EGCG treatment attenuates T cell proliferation in CIA. Cells from the dLN of CIA mice sacrificed seven weeks after CIA induction were cultured
for 72 h in the absence or presence of a 10 ug/ml CII or b anti-CD3 antibody. After pulsing with 1 uCi of [3H] thymidine per well for the last 18 h,
proliferation was measured as [3H] thymidine incorporation in counts per minute (cpm). Results shown are representative of data from 4 to 5 mice per
group from three independent experiments with similar numbers of mice; ∗∗∗P < 0.001. c,d 5,6-carboxyfluorescein succinimidyl ester (CFSE)-labeled
dLN cells were cultured with type II collagen for 72 h, followed by flow cytometric analysis of CD4+ T cells; ∗P < 0.05. Data are representative of one
sample (histograms) and one experiment (graph) from three independent experiments with 4 to 5 mice per group per experiment
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(CFA), shares a number of relevant features with human
RA. By evaluating the molecular and cellular effects of
green tea polyphenols or EGCG in different autoimmune
models, these studies have brought to the forefront the
beneficial effects of EGCG in modulating inflammation in
animal models of experimental autoimmune encephalo-
myelitis (EAE) [18], lupus-like and other immune-mediated
glomerulonephritis [17, 35], spontaneous non-obese
diabetic mice [37] and Sjogren’s syndrome [38]. Our
studies indicated that green tea extract or EGCG adminis-
tration improved symptoms of arthritis, pathological fea-
tures, and decreased serum CII-specific IgG2a antibody
levels. In addition, EGCG treatment markedly reduced
inflammation-related cytokine production including IFN-γ,
IL-6 and TNF-α whereas it increased the production of
IL-10. The present report adds mechanistic insights to
previous observations that EGCG can be beneficial in
arthritis models [20].
EGCG has been reported to modulate lymphocyte,
neutrophil, macrophage and dendritic cell functions
[16, 21, 39–43]. In in vitro cultures, EGCG altered B
and T cell proliferative responses [16, 41, 43, 44]. Using a
mixed lymphocyte culture assay it was evident that green
tea extract significantly inhibited the proliferation of murine
lymphocytes after stimulation with a potent T cell mitogen
[45]. Our studies demonstrate that the total number of cells
isolated from dLN were significantly lower in EGCG-
treated than vehicle-fed CIA mice (P < 0.01). EGCG also
suppressed the proliferation of autoreactive T cells and to a
lesser extent, mitogen-stimulated T cells as measured by
3H-thymidine incorporation. These studies parallel the
changes observed in the CII antigen-specific T cell division
assays using the tracking dye CFSE, which indicated that
EGCG suppressed T cell proliferation. In a previous study,
it was found that EGCG might inhibit T cell proliferation




































Fig. 5 EGCG treatment increases IDO expression and activity in CD11b+ cells. CIA mice were fed with EGCG or PBS (vehicle) for 7 weeks after CIA
induction and (a,b) dLN sections were stained for CD11b and IDO, respectively (magnification: X200). Photomicrographs and graph shown are
representative of three independent experiments with 4 to 5 mice per group. (c,d) Expression of IDO in CD11b+ cells from dLN and spleen were
analyzed by flow cytometry. Data are representative of three independent experiments with a total of 14 mice per group. (e) Functional IDO activity in
freshly isolated CD11b+ cells was measured by the production of kynurenine in the culture supernatants of sorted DC as detailed in the methods.
CD11b+ DC from spleens were sorted and incubated in HBSS for 4 h. Studies were performed in triplicate and repeated at least twice with
similar results; in total seven mice were examined from each group
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induce IFN-γ production and IL-2 blockade can lead to the
inhibition of IFN-γ production [28, 43, 45], and this might
underlie some of the observations in the current study. Re-
cently, it was found that EGCG also inhibits B lymphocyte
proliferation and induces B lymphocyte apoptosis [44].
Consistent with this, we found that EGCG administra-
tion reduced total dLN B cell (CD5−B220+) frequencies
as well as percentages of major splenic B cell subsets
including follicular (Fo, CD21intCD23hi) and marginal
zone (MZ, CD21hiCD23lo) B cells. Taken together, we
conclude that EGCG suppresses both T and B cell expan-
sion induced by CII in arthritic mice as EGCG effected
both the frequency and absolute numbers of cells.
Previous reports have described the correlation between
the decreased function and/or percentage of CD4+CD25+
Treg cells in patients with RA and clinical disease activity
[46]. Moreover, CD4+CD25+ T cells isolated from arthritic
animals were capable of exerting suppressor function in
in vitro assays [47], while it has been shown that the de-
pletion of CD4+CD25+ cells could lead to the spontaneous
development of autoimmune diseases and increased sever-
ity of symptoms in CIA mice [48]. In an EAE model,
EGCG also reduced the production of IFN-γ, IL-17, IL-6,
IL-1β and increased Treg numbers in lymph nodes and
spleen [18]. In agreement with previous findings, the
current study showed that EGCG–fed mice exhibited in-
creased percentages of CD4+ CD25+ Foxp3+ Treg cells
when compared with vehicle-fed CIA mice. These results
are also consistent with the findings of other investigators























CIA EGCG + 1MT
CIA EGCG
Fig. 6 IDO+CD11b+ DC induce antigen-specific CD4+CD25+ Tregs and are juxtaposed to Tregs. Increased generation of CD4+CD25+ Foxp3+ T cells
is mediated through an indoleamine 2,3-dioxygenase (IDO)-dependent mechanism. a,b For regulatory T cell induction, isolated CD4+CD25− T cells
(1 × 105/well) were cultured for three days with CD11b+ DC (1 × 105/well) from EGCG-fed or vehicle-fed CIA mice in the absence or presence of
type II collagen (CII, 10 μg/ml). 1-MT was added to the indicated cultures. CD4+ cells were first gated and then plotted as CD25 versus
Foxp3 as determined by flow cytometry. Numbers represent the percentage of CD4+ CD25+ Foxp3bright positive cells and are representative of three
independent experiments. c Immunofluorescent analysis of IDO and Foxp3 expression in the spleen. Spleens from EGCG-fed or vehicle-treated CIA
mice were fixed and stained with antibodies specific for mouse IDO (red) and Foxp3 (green); original magnification, X200. Photomicrographs shown
are representative of three independent experiments. d Arthritis scores for vehicle-fed, EGCG-fed, or EGCG-fed mice given 2 mg/ml of 1-MT solution in
drinking water bottles for three weeks. Values are presented as the mean ± standard error of the mean, and represent two independent experiments;
in total eight mice were examined for each group
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modestly enhances Foxp3 and IL-10 mRNA expression
in a CD4+ T cell line [49].
This study is in agreement with previous reports that
IDO expressing innate immune cells can help generate
Tregs. For example, human IDO expressing plasmacytoid
DC triggered by TLR ligation induced the generation of
CD4+CD25+Foxp3+ Tregs from CD4+CD25− T cells [50].
Other studies also support this result as CD11c+CD11b+
DCs isolated from peyer's patches of orally tolerized mice
with type II collagen appeared to be necessary for the
expansion and differentiation of CD4+CD25+ T cells,
which suppressed CII-specific T-cell proliferation [31].
These studies support our observation that CD11b+ DCs
isolated from EGCG-fed mice express high levels of
IDO and can facilitate the generation of Ag-specific
CD4+CD25+ Foxp3+ Tregs. Blocking IDO activity with
the specific inhibitor, 1-MT, significantly abrogated the
proportion of CD4+CD25+ Foxp3+ T cells induced by
CD11b+ DCs from EGCG-fed CIA mice. Thus, these data
support the hypothesis that EGCG-induced IDO-expressing
CD11b+ DCs can generate Tregs from CD4+CD25− cells in
CIA mice.
Previously, antioxidants and antioxidative enzymes have
been shown to reduce cartilage damage in animal models
of RA, with Nrf2 being a major player [51, 52]. Moreover,
Nrf2 deficiency leads to an acceleration of the effector
Fig. 7 EGCG induces IDO-dependent Nrf-2 activation in joints of CIA mice. a Representative western blots for Nrf-2, phosphorylated Nrf-2 (pNRF2),
and HO-1 expression in joint homogenates. b Densitometry results for pNrf2, Nrf2 and HO-1 as shown in (a) as relative fold change compared to
the GAPDH loading control. Results are the mean ± SD of replicate samples, representative of three independent experiments. c Representative western
blots for Nrf-2, pNRF2, and HO-1 expression from joint homogenates of vehicle-fed, EGCG-fed or EGCG-fed + 1-MT treated CIA mice. d Densitometry results
for pNrf2, Nrf2 and HO-1 are shown for (c) as relative fold change compared to the GAPDH loading control. Results are representative of three independent
experiments, with 4 to 5 mice per group. e Immunohistochemical staining, original magnification, X200, for pNrf2 in knee sections from
vehicle-fed, EGCG-fed or EGCG-fed + 1-MT treated CIA mice (upper panel). Cartilage degradation was revealed by safranin-O staining of paw
sections from vehicle-fed, EGCG-fed or EGCG-fed + 1-MT treated CIA mice (lower panel). Results are representative of three independent experiments
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phase of arthritis [52]. It has also been reported that Nrf2
activity inversely correlates with disease in RA patients
[53]. Our data demonstrate that EGCG treatment signifi-
cantly increased pNrf2 activity, and increased expression
of HO-1, a Nrf2 target gene. Devesa and colleagues have
reported that induction of HO-1, which is protective
against joint destruction, can exert partial anti-arthritic
effects in CIA [54]. Recently, it has been found that
pharmacological up-regulation of HO-1 causes a ro-
bust anti-inflammatory response in a model of non-
autoimmune arthritis in mice [55], and might prove to
be a novel therapeutic target in treatment of chronic
inflammatory diseases. Thus, the finding that EGCG
enhanced Nrf2 activity resulting in increased levels of
HO-1 is of considerable significance.
Of note, activation of Nrf2 in T cells by tert-
butylhydroquinone (tBHQ), inhibits production of
the Th1 cytokine, IFN-γ [56]. Maicas et al. reported
that deficiency of Nrf2 resulted in increased migration of
pro-inflammatory cells into the joints during the develop-
ment of arthritis, with significant elevations in TNF-α and
IL-6 levels compared with wild type controls [51]. This is
also consistent with reports indicating that CD4+ T cells
from Nrf2 null mice secreted increased amounts of IFN-γ
whereas levels of IL-4, IL-5 and IL-13 are decreased [51].
In addition, several reports have demonstrated that a
deficiency in Nrf-2 activity results in greater sensitivity to
oxidative and inflammatory disorders such as asthma,
colitis and sepsis [57–59]. Recently, a chronic granu-
lomatous disease (CGD) patient was found with un-
detectable IDO metabolic activity, increased Th17 cells
as well as impaired transcription factor Nrf2 activity [60].
CGD is an inherited immunodeficiency characterized by a
hyper-inflammatory response and an inability to produce
reactive oxygen intermediates (ROI), which might lead
to impaired counter-regulation by the IDO pathway
and insufficient Nrf2 activation [32, 61]. Interestingly,
our data revealed that EGCG-fed CIA mice had signifi-
cantly decreased levels of IFN-γ IL-1β, IL-6 and TNF-α
and increased IL-10 levels in joint homogenates and
serum as compared to vehicle-fed CIA mice supporting
the observation that increased Nrf2 activity correlates
with suppression of the inflammatory response.
Collectively, our studies and previous work support a
model whereby EGCG-induced Nrf2 activation may skew
T cells from a Th1/Th17 phenotype to a Th2 and Treg
phenotype and this finding warrants further investigation.
The current study is the first to report a relationship be-
tween the effects of EGCG treatment and the induction of
IDO expression, an activity which can then upregulate anti-
oxidant pNrf-2 activity in mice with arthritis. Further stud-
ies are required to determine the clinical relevance of these
findings and a systematic testing of potential therapeutic
targets in this regulatory cascade.
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